A switch to infliximab may be more effective than ustekinumab following adalimumab pharmacodynamic failure in paediatric patients with Crohn’s disease
Digestive and Liver Disease · 2025
DOI: 10.1016/j.dld.2025.06.021 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Galit Driban und 9 weiteren Autor:innen. Beteiligte Einrichtung: Juliet Keidan Institute of Paediatric Gastroenterology, Hepatology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Centre, The Hebre…. Hauptthemen laut MEDLINE: Crohn Disease, Ustekinumab, Adalimumab, Infliximab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Juliet Keidan Institute of Paediatric Gastroenterology, Hepatology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Centre, The Hebrew University, Jerusalem, Israel. Electronic address: galitd11@gmail.co…
- Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Centre of Israel, Petach Tikva, Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
- Juliet Keidan Institute of Paediatric Gastroenterology, Hepatology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Centre, The Hebrew University, Jerusalem, Israel.
- Division of Paediatric Gastroenterology and Nutrition, Sheba Medical Centre, Edmond and Lily Safra Children's Hospital, Tel-Hashomer, Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
- Paediatric Gastroenterology Institute, "Dana-Dwek" Children's Hospital, Tel Aviv Sourasky Medical Centre and the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Paediatric Gastroenterology and Nutrition Institute, Ruth Children's Hospital of Haifa, Rambam Medical Centre, Faculty of Medicine, Technion, Haifa, Israel.
Zitieren
APA
Driban, G., Matar, M., Lev-Tzion, R., Ledder, O., Granot, M., Yerushalmy-Feler, A., Magen-Rimon, R., Zifman, E., Turner, D., & Assa, A. (2025). A switch to infliximab may be more effective than ustekinumab following adalimumab pharmacodynamic failure in paediatric patients with Crohn’s disease. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.06.021
Vancouver
Driban G, Matar M, Lev-Tzion R, Ledder O, Granot M, Yerushalmy-Feler A, et al. A switch to infliximab may be more effective than ustekinumab following adalimumab pharmacodynamic failure in paediatric patients with Crohn’s disease. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2025.06.021
BibTeX
@article{Driban2025,
author = {Driban, Galit and Matar, Manar and Lev-Tzion, Rafi and Ledder, Oren and Granot, Maya and Yerushalmy-Feler, Anat and Magen-Rimon, Ramit and Zifman, Eyal and Turner, Dan and Assa, Amit},
title = {A switch to infliximab may be more effective than ustekinumab following adalimumab pharmacodynamic failure in paediatric patients with Crohn’s disease},
journal = {Digestive and Liver Disease},
year = {2025},
doi = {10.1016/j.dld.2025.06.021}
}
EUVIMED